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Randomized controlled trials and meta-analyses provide evidence for the efficacy of 
cognitive-behaviourally informed treatment (CBT) programmes for chronic pain.  The 
current study aims to provide practice-based evidence for the effectiveness of CBT in 
routine clinical settings.  Over a 10 year period 1013 pain patients were accepted into a 4 
week in-patient pain management programme.  Data from more than 800 patients was 
available at pre-treatment and at one month post-treatment and for around 600 patients at 
pre-treatment and at 9 months follow-up.   Measures reported in this analysis were pain 
experience and interference, psychological distress (depression and anxiety), self-
efficacy, catastrophizing, and walking.  Change from pre-treatment to post-treatment and 
follow-up was assessed with conventional statistical tests, the computation of effect sizes 
and by the reliable change index (RCI) and clinically significant change (CSC) 
methodology.   These analyses provide evidence of statistical improvement at post-
treatment and follow-up and the RCI/CSC methodology suggested that between 1 in 3 
and 1 in 7 (depending on the outcome measure) achieved clinically significant gains.  
There was also evidence that a small percentage of patients (1% - 2%) reliably 
deteriorated during the period of treatment.  The limitations in the inferences that can be 
drawn from this study and of the methodology are discussed.  A case is made for the 
application of benchmarking methods using data from RCTs in order to more fully 




The practice of evidence based medicine is espoused by many governments and 
health care organisations.  The aims of evidence based medicine include the allocating of 
effective treatment in a timely and efficient manner and, increasingly in socially 
regulated health care systems, managing access to scarce resources.  The basis of 
evidence based medicine are high quality randomized controlled trials (RCTs) and 
integration of their results through systematic review and meta-analysis [41; 42].  
Psychologically based treatments for chronic pain as a generic condition, or for specific 
diagnostic groups where pain is a significant symptom and problem e.g. rheumatoid and 
osteo-arthritis, have developed over 40 years; many RCTs and several meta-analyses 
attest to treatment efficacy under controlled conditions in comparison with both wait list 
and control treatments [44; 12; 27].  
While RCTs and meta-analysis have been used to establish the efficacy of 
psychological treatments they do not necessarily provide evidence of effectiveness: 
whether the treatment provides a measurable beneficial effect when delivered to patients 
in other service contexts [4].  Generalising from RCTs to other contexts is problematic 
where there is less control over, for example, selection and recruitment of patients, 
implementation of treatment to a manualized standard, or checks on the adherence and 
delivery of the therapeutic protocol [55].  What is required is evidence from clinical 
practice, i.e. practice based evidence such as that described by Barkham and Mellor-
Clark [4], for the effectiveness of treatment.  These authors and others argue that a model 
of research into efficacious and effective treatment should be based on a cycle in which 
evidence based practice (EBM) informs clinical practice which then generates evidence 
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and questions (practice based evidence) for testing under more controlled conditions of 
EBM. 
The aim of this article is twofold:  It seeks to generate evidence from routine 
clinical practice for the effectiveness of a cognitive behavioural pain management 
programme and in doing so it identifies issues concerning the way in which the majority 
of RCTs in this field measure and report outcomes.  Most trials of psychological 
treatments use continuous measures and the subsequent analyses focus on differences 
between group means at the end of treatment (suitably controlled for pre-treatment 
differences and other confounds) that are evaluated with conventional inferential statistics 
(P values).  Aside from the fact that P values are sensitive to sample size, the test 
statistics are not generally referenced to any external criterion.  This methodology is not 
useful for evaluation of treatment where there is no control group, as is typical in clinical 
practice.  In these situations, pre-post treatment differences may be computed but provide 
no information about the clinical significance of changes. In the current study we 
employed Reliable Change Index (RCI) / Clinically Significant Change (CSC) 
methodology [30; 29] to evaluate a 4 week in-patient CBT rehabilitation programme for 
chronic pain.   
2. Methods 
The data reported in this study were collected as part of routine procedure by the 
clinic.  The data were available in an anonymised database.  Permission to access and 
interrogate the database using an explicit protocol was given by the relevant UK NHS 
Trust research ethics committee. 
2.1. Overview of sample and data collection 
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Between 1989 and 1998, 2041 patients attended a publicly funded (UK National 
Health Service) pain management service.  The service is a specialist tertiary one that 
receives referrals from other pain clinics, general practice, orthopaedic and other 
specialist services from around the UK.  Primary assessment was made by anaesthetists 
and clinical psychologists. The exclusion criteria were: inability to speak English, 
inability to climb stairs, current major psychiatric disorder (active psychosis, severe 
depression with high risk of suicidal attempt), suitable for further medical treatments 
following examination, pain duration less than one year, current opioid misuse (either 
chronic illegal opioid use or in a methadone maintenance programme). Patients were 
required to meet two of the following inclusion criteria: widespread disruption in non-
work and/or work activity due to pain, habitual over-activity leading to increased pain, 
use of high levels pain medication with little reported benefit, high affective distress 
score, unnecessary use of medical aids, high levels of pain behaviour.  Patients completed 
a package of assessments (see below) administered by assistant psychologists and others 
who were not part of the treatment team.  During the period 1989-1998, several treatment 
options were trialled including 2 and 4 week programmes with in-patient and out-patient 
options.  This article reports the outcomes for patients who attended a 4 week long in-
patient programme and provided data at baseline (pre-treatment).   Data were collected 
pre-treatment, one month post-treatment (post-treatment) and at 9 months follow-up 
(follow-up). There is variation in the number of data points available for each of the 
measures for two reasons: attrition at post-treatment and follow-up, and because over the 
10 year period the programme occasionally changed measures, supplementing or 
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replacing measures as they were improved.  The sample sizes varied between 833 for pre-
treatment/post-treatment comparisons and 527 for pre-treatment/follow-up comparisons. 
2.2. Programme description 
Williams et al (1999: p.60) [57] have previously described this programme as 
follows: “The unit was staffed by a consultant anaesthetist, two clinical psychologists, a 
physiotherapist, an occupational therapist, a senior nurse, and a secretary/administrator. 
The program was based on the work of Fordyce [20], Keefe and colleagues [23], [47], 
and Turk et al. [53] and incorporated operant and cognitive behavioural principles in all 
aspects.  No other active treatments (such as nerve blocks or acupuncture) were offered 
once patients were accepted for the program. Treatment was carried out in hospital 
premises with hostel-type accommodation for in-patients who lived independently 
outside program hours and returned home at weekends. The in-patient programme was 
carried out over four weeks, four and a half days per week.  
The program consisted of the following components, all supported by written 
materials: education concerning pain, disuse, drugs, and sleep; exercise routines for 
fitness, flexibility and muscle minimum strength, increasing gradually on a quota system; 
goal setting across all activities with quota increases and activity-rest scheduling 
(pacing); psychology sessions to improve problem solving, change maladaptive 
behaviours and to maintain those changes, with cognitive  techniques to identify 
unrealistic and unhelpful thoughts and beliefs, and to challenge and change them; drug 
reduction applied to all pain-related drugs which had neither achieved analgesia nor 
improved function, with the usual aim of abstinence by discharge; applied relaxation; 
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relapse prevention and planning for crises; and sleep hygiene. Spouses and family 
members (where available) were involved in a small number of sessions.” 
2.3. Measures 
The measures described in this section include those for which data was 
consistently collected in the 10 year period.  During this period several other measures 
were trialled and either excluded or too few data were available for analysis.  In order to 
obtain estimates of reliability and to set appropriate cut scores needed to determine RCI 
and CSC criteria, we carried out systematic searches of the literature for each measure.  
The results of these searches are briefly summarised for each measure.  Computation of 
the RCI requires the standard deviation of the measure (obtainable from the sample) and 
an estimate of the reliability of the measure.  Reliability data was obtained from 
published reports and wherever possible we used measures of internal consistency 
(Cronbach’s α or the intraclass correlation coefficient).  The measures of pain experience 
were single item measures for which internal consistency assessments are not possible: in 
these cases we used reliability based on stability (test-retest). The type of reliability 
coefficient and the values used in this study are shown in Table 1.  
Jacobson’s [29] determination of a clinically significant criterion employs 
statistical criteria to establish cut scores for continuous variables that essentially use the 
properties of the normal distribution.  The criteria (a), (b) and (c) are defined as follows: 
(a) is achieved when the post-treatment (or follow-up) score lies outside of the range of 
the dysfunctional population, where the range is defined as extending 2 SD units beyond 
the mean for that population in the direction of a functioning population; (b) is achieved 
when the post-treatment (or follow-up) score lies within the range of the functioning 
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population, where the range is defined as within 2 SD units of the mean of the 
functioning population;  and (c) is defined as when the post-treatment (or follow-up) 
score is statistically more likely to be in the functional population – i.e. nearer to the 
mean of the functional population than the mean of the dysfunctional population.  For 
practical reasons the sample of participants was regarded as the population.  We then 
used the following rules to determine which criterion to apply for each measure.  If 
distributional data were available from a suitable normative (functional) control sample 
we elected to use criterion (c).  When no control sample was available we used criterion 
(a).    In addition to Jacobson’s criteria we used a normative criterion (n), determined by 
reference to established cut scores for the test.  For example, the authors of the Hospital 
Anxiety and Depression Scale (HADS) [59] indicate that a score of 8 on each subscale 
may be regarded as a reasonable cut score for defining the presence of clinical levels of 
depression and anxiety.  Details of the selected cut score are provided for each measure 
and a summary is shown in Table 1.  
2.3.1. Pain experience (intensity, distress and interference) 
Average pain intensity, pain distress and interference attributed to pain were 
measured on 0-100 (101 point) numerical rating scales (NRS) [32].  The literature search 
revealed several studies comparing the relative performance of scale types for these three 
constructs but information on test-retest reliability was sparse. The preferred internal 
consistency measure of reliability cannot be used on these measures as they are single 
item measures.  Zautra et al. [58], reported 2-week test-retest correlations for the 101-
point scale of 0.69 in a sample of women with fibromyalgia.  Similar searches for distress 
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and interference failed to produce clear guidance and we therefore adopted the 0.69 
estimate of reliability.   
Several recent studies have sought to establish criteria for judging clinically 
significant changes in pain intensity [17; 19; 8; 9; 18; 11; 25] in both acute and chronic 
pain and the value converges at about 30% change from the initial score.  We therefore 
adopted this criterion for a clinically significant change for all three measures based on 
the NRS scales.  Unlike the other CSC used in this study, the criterion for these three 
measures is ipsatized to the patient’s baseline score and not set at a discrete score on the 
scale.  
2.3.2. Beck Depression Inventory 
The original 21 item BDI was used. We adopted α = 0.81 as the reliability 
coefficient from a review of the scale by [5].  A literature search revealed several studies 
comparing pain patients with and without depression as defined by DSM criteria. We 
identified one by [21] which used a sample of chronic pain patients with similar 
characteristics as the current sample.  The data from Geisser at al. [20] was therefore used 
to establish a clinically significant change criterion (c) cut score of 19.68. 
2.3.3. Hospital Anxiety and Depression Scale (HADS) 
The HADS was developed as a measure of depression and anxiety to be applied in 
medical settings where patients are likely to have somatic symptoms attributable to a 
primary somatic illness rather than their mental health.  The 14 items (7 each for 
depression and anxiety) therefore eschew reference to somatic manifestations of the 
target psychological states.  The HADS has been widely used in many settings and has 
good internal consistency. Zigmond and Snaith [59] originally suggested that scores 
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above 8 on each of the scales was indicative of clinical levels of anxiety and depression.  
Lowe et al. [37] have shown that this cut score appears to give optimal specificity and 
sensitivity.   
2.3.4. Coping Skills Questionnaire Catastrophizing subscale (CSQ-Cat) 
The CSQ is widely used to assess various aspects of coping.   The original scale 
devised by Rosenstiel and Keefe [49] comprises 42 items and 7 subscales.  Twenty years 
of research has established the critical role that catastrophizing plays in the maintenance 
of distress in chronic pain [50].  Reduction of catastrophizing is correlated with better 
emotional and behavioural outcomes in psychological treatment programmes [33; 6].  We 
therefore selected this subscale as a key indicator of cognitive change.  The 
catastrophizing subscale consists of six items that address negative thoughts about pain as 
well as catastrophic thinking. Individuals are asked to rate the frequency of thoughts 
when they experience pain using a 7-point scale ranging from 0 (never) to 6 (always). 
The six items on the CSQ catastrophizing scale have been shown to have good internal 
reliability as well as a high degree of stability over time [35].  We selected the original 
estimate of α = 0.78 [47] as the reliability coefficient and used Jacobson’s (c) criterion to 
establish a clinical significant cut score. 
2.3.5. Pain Self Efficacy Questionnaire (PSEQ) 
The 10 item self-report PSEQ was developed as a pain specific assessment of 
Bandura’s concept of self-efficacy; a person’s beliefs about their ability to perform a 
particular behaviour in the face of “obstacles and aversive experiences” [3].  Examples of 
items include “I can still do many of the things I enjoy doing, such as hobbies or leisure 
activity, despite the pain”.  Respondents rate their belief in their ability to perform 10 
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activities on a seven-point scale ranging from 0 (not at all confident) to 6 (completely 
confident). Scores range from 0 to 60 with higher scores indicating stronger self-efficacy 
beliefs. The PSEQ has been shown to have good test-retest reliability and internal 
consistency [22; 1].  Asghari and Nicholas [1] report an internal consistency value α = 
0.92 which was used to assess the RCI.  In the absence of a suitable control groups 
criterion (a) was used to set a clinically significant cut score. 
2.3.5. 5-minute walk 
The 5-minute walk test from a battery used to assess physical performance was 
selected as a behavioural outcome measure. The performance tests [26] were designed 
develop and normed by personnel involved in the pain management programme. The 5-
minute walk test was derived from a longer 10-minute version and involves the patient 
walking up and down a corridor for the prescribed time. Patients were allowed to use the 
walls for support or to sit down where necessary and the number of meters walked was 
noted. Harding et al. [26] report excellent reliability for the 10-minute walk test (ICC = 
0.94) and report that the 5-minute version is a reasonable alternative as both are highly 
correlated (r = 0.99).  Jacobson’s criterion (a) was used to set a clinically significant cut 
score. 
2.4. Data Analysis 
Possible bias attributable to attrition was checked by comparing the sub-sample 
available at each stage with drop-out sub-samples on demographic characteristics and the 
measure in question.  Outcomes of the programme were evaluated by computing 
conventional inferential statistical tests and estimates of effect size, reliable change 
indices and the proportion of individuals achieving clinically significant change. 
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3. Results 
3.1. Sample description 
At pre-treatment 61.8% of the sample were female.  Information on ethnic origin 
was available for 997 patients: the majority was white Caucasian (90.1%), with 3.8% 
Afro-Caribbean and 2.9% Asian. The average age of the sample was 45.7 years (SD = 
11.7; range 18-84 years; median 46 years).  Information on employment and social 
economic status was available for 994 individuals. Of these 6.1% were employed, a 
further 6.8% were employed but restricted by their pain, 27.7% were unemployed and 
this was largely attributed to pain, a substantial number were classed as permanently 
sick/disabled (38.9%); the remaining patients were retired (11.8%), homemakers (5.1%) 
or students (0.7%).  With respect to occupational status 50.1% were classified as skilled 
manual/clerical, 25.9% as professional/managerial and 11.3% as unskilled manual.  The 
majority of patients were receiving sickness or disability related income (70.4%) and for 
some (34.6%) this was the main source of income.  Information regarding previous and 
current legal action was available for 956 patients. 20.1% were or had been involved in 
legal action; 74.2% of the sample was not involved in legal action. 
The primary sites of pain were low back (62.7%), shoulder and upper limb 
(10.0%), lower limb (9.4%), neck (6.5%), abdomen (2.8%), head (3.0%), chest (2.2%), 
perineum, rectum and genital area (2.6%) and pelvis (1.5%). The mean time since onset 
was 113.2 months (SD = 108.3; range = 3-677; median 74 months). The majority were 
taking medication (95.6%).   
3.2.   Attrition 
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There were data on at least one measure pre-treatment for 1013 patients.  Post-
treatment data were available for between 720 and 833 patients depending on the 
measure, and at follow-up the range of sample sizes varied between 527 and 639.  
Information on reasons for attrition was not available.  There were no systematic biases 
attributable to demographic characteristics or baseline values of the key measures. 
3.3. Conventional statistical tests and effect size estimates 
Table 2 shows the mean values and standard deviations for each variable at each 
time point and the sample size at each point of measurement.  The reported values for the 
pre-treatment data are based on the sample sizes used in the pre-treatment to post-
treatment comparisons and these values were not significantly different to the values 
obtained when the reduced sample available for pre-treatment to follow-up comparisons 
were made.  Conventional statistical tests were conducted with repeated measures 
ANOVA and t-tests.  All pre-treatment to post-treatment and pre-treatment to follow-up 
comparisons involved large sample sizes (n > 500) and were significant with P levels 
beyond .001.   
The magnitude of pre-treatment to post-treatment and pre-treatment to follow-up 
differences was also expressed as a series of effect sizes and their 95% Confidence 
Intervals (95%CI).  Table 2 also displays the correlations for each measure across the 
occasions of testing and the corresponding pair-comparison t-test values.  These data 
were used to compute estimates of effect size (d) and its variance (var(d)) for correlated 
data [14]: 
d = tc [2(1-r)/n]½  and  var(d) = [2(1-r)/n] + [d2/(2n-2)] 
Where, tc = the value of correlated t-test statistic; r = correlation, n = sample size. 
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The estimates of the effect sizes and their 95% confidence intervals for both pre-
treatment to post-treatment and pre-treatment to follow-up comparisons are displayed in 
Figure 1.  The range of values for the pre/post comparison, displayed as a filled circle, 
was 0.26 (pain intensity) to 0.73 (PSEQ) with a median value of 0.51.  The corresponding 
values for the pre-treatment to follow-up comparisons, displayed as an open circle, were 
0.27 (pain intensity), 0.62 (PSEQ) with a median value of 0.41.  In every case the lower 
bound confidence limit for the effect size was greater than 0 indicating that the mean 
value of the sample is reliably greater than the point of no change. 
3.4. Reliable Change Index (RCI) and Clinically Significant Change (CSC) 
The RCI and Jacobson’s CSC criterion (a) was computed for each measure using 
the available reported reliability coefficients cited in the Measures section (above) and 
the standard deviation of the sample at pre-treatment assessment.  The combination of 
RCI and CSC criteria enables patients to be classified into a number of outcome groups: 
these are represented schematically in a ‘tramline display’ shown in Figure 2 [43].  The 
figure schematically represents the scores from a measure obtained at pre-treatment and 
post-treatment, in which a reduction in the score represents an improvement.  The main 
diagonal (dotted line) represents scores that do not change during the period of 
measurement.  The symmetrical parallel lines either side of the main diagonal represent 
the upper and lower boundaries of the RCI which, in this case have been set with a 
confidence interval (CI) of 95%.  The figure also includes 8 points, labelled i to vii 
representing individuals who illustrate several possible combination of pre- and post-
treatment scores corresponding to distinct outcomes.  Data points (ii and vii) that fall 
within the confines of the RCI confidence intervals may therefore be regarded as 
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representing ‘no change’ i.e. the magnitude of any change is explained by the error 
attributable to the imperfect reliability of the measure.  Data points outside of the 
confidence intervals (all other points) can be considered as representing a change that is 
not likely to be accounted for by the unreliability of the measure, i.e. ‘genuine change’.  
In Figure 2 individuals iii, iv and viii show a reliable improvement from pre-treatment to 
post-treatment while individuals i, v and vi show a reliable deterioration at post-
treatment.  (We acknowledge that the effect of statistical regression [7] would be to rotate 
the line of no-change line and its confidence intervals away from the main diagonal.  
Minor adjustments to the RCI may be made by incorporating the expected regression 
effect into the computation of the RCI [28; 24].  Results of a recent large scale simulation 
study concluded that the traditional RCI computations are sufficient [2].) 
In Figure 2 the CI has been set at the conventional 95%.  This may be regarded as 
a somewhat conservative in that it sets a reasonably stringent criterion for defining 
change.  The criterion may by relaxed by choosing another parameter e.g. 90%, the effect 
of this will be to contract the CI lines toward the main diagonal, as a consequence more 
individuals will be classified as changed.  This aspect of selection of the CI magnitude is 
a function of investigator preference and the need to weigh the balance between Type 1 
and Type 2 errors in defining change.  The magnitude of the CI is also affected by the 
reliability of the test and the variance of the sample.  Increasing the reliability of the test 
and decreasing the variance of test scores will both decrease the magnitude of the 
boundaries of the CI for a given criterion value (95% or 90%).  
Figure 2 also illustrates the implications of imposing a defined criterion for 
assessing clinically significant change.  In the figure the CSC cut scores have be 
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superimposed as reference lines on both the pre-treatment (x-axis, vertical line) and post-
treatment (y-axis, horizontal line) scales.  These reference lines separate the sample into 
individuals who are above and below the CSC criterion at each occasion of measurement. 
In Figure 2 high scores on the scale indicate dysfunction (e.g. high levels of distress or 
interference in daily activities).  Thus data points (i, ii, iii and iv) to the right of the pre-
treatment cut score (vertical line) represent individuals who were above the defined 
clinical cut point at pre-treatment assessment, while data points v to viii represent 
individuals who were below the clinical criterion at pre-treatment.  The horizontal line 
represents the cut-point superimposed on the post-treatment axis: points above the line 
represent patients who remain ‘dysfunctional’ at post-treatment and data points below 
represent patients who are below the criterion set for clinical significance.  One important 
feature of the present data is that at pre-treatment a significant proportion of the current 
sample was below a CSC criterion for some of the measures.  This situation arose 
because the selection criteria used did not require patients to meet these criteria for 
admission to the programme: for instance, high levels of distress (high scores on the BDI 
and HADS) were not a prerequisite for entry.   
The combination of RCI and CSC criteria enables patients to be classified into a 
number of outcome groups. As consequence an expanded range of outcomes is possible.  
For those patients above the CSC criterion at pre-treatment there are four possible 
outcomes (i to iv in Figure 2): 
i. reliable deterioration from their pre-treatment level 
ii. no change 
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iii. reliable improvement but not to such a degree that they may also be regarded 
as clinically improved 
iv. clinical significant change i.e. reliable change and the post-treatment score 
exceeds the clinical criterion 
For those patients below the CSC criterion at pre-treatment there are also four possible 
outcomes. 
v. clinically significant deterioration i.e. reliable change and post-treatment score 
above the cut point 
vi. reliable deterioration – but not to such a degree that the post-treatment score 
exceeds the cut point for clinical significance 
vii. no change 
viii. reliable improvement 
There are thus eight possible outcomes when the sample is spread across the pre-
treatment CSC cut score.  To capture this aspect of the analysis the sample was divided 
into those above and below the defined CSC criteria at pre-treatment and the criteria for 
reliable and clinically significant change applied to each subset of the data.  The 
summary statistics, frequencies and rounded percentages for the complete sample in each 
of the categories i to viii, are shown in Table 3.   
As noted, the method used to set CSC criterion meant that there were no pre-
treatment observations below the criterion for the three pain related measures (intensity, 
distress and interference).  The majority of individuals were categorized as unchanged for 
these measures with a significant minority achieving a clinically significant change of 
more than 30% reduction in their scores from baseline.  The response rate for achieving a 
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clinically significant change ranged from about 1 in 8 for pain intensity to 1 in 4 for pain 
interference.  It is also notable that no patients fell into the reliable change category (ii).  
This is attributable to a statistical quirk in that the degree of change necessary for a 
reliable change exceeded the value required to meet the CSC criteria (see Table 1).  This 
position would change with increased reliability of the measure, currently set at 0.69 for 
all measures, or by altering the CSC criteria.  
The CSC criterion for the three scales assessing distress assigned a significant 
proportion of the sample below the cut point at pre-treatment (BDI 55%; HADS anxiety 
22%; HADS depression 30%).  When only those above the CSC criterion are considered, 
the response rate for achieving a CSC ranged from about 1 in 3 (33%, BDI) to 1 in 4 
(25%, HADS depression) to just over 1 in 5 for the HADS anxiety scale (18%).  A 
further smaller number achieved a reliable improvement that did not reach clinical 
significance (BDI, 5%; HADS anxiety 12%; HADS depression 9%).  The remaining 
measures, CSQ, PSEQ and 5 minute walk test, all used Jacobson’s criterion (a) which set 
the CSC criterion at the extreme tail of the clinical sample.  As a consequence relatively 
few patients are assigned below the CSC criterion at pre-treatment.   The response rates 
for those above the CSC criterion ranged from about 17% (PSEQ) to 4% (CSQ 
catastrophizing) and 6% (5 minute walk test).  Relatively more patients achieved a 
reliable change (CSQ catastrophizing = 15%; PSEQ = 33%; 5 minute walk = 34%).  
When taken as a whole, individuals who were below the CSC criteria for the pre-
treatment measures remained below the criteria at post-treatment.  The majority of scores 
were essentially unchanged but a few individuals made some reliable gains.  A few 
showed reliable deterioration but did not exceed the CSC criterion, and a small number 
 18
did show what might be regarded as clinical deterioration.   There was also evidence that 
a small number of patients above the CSC criteria at pre-treatment showed deterioration 
at post treatment.  A similar pattern of responding was shown at follow-up. 
4. Discussion 
The main aim of this study was to establish evidence for the effectiveness of CBT 
for the management of chronic pain in a routine clinical setting and to explore different 
methodologies for assessing outcome.   The conventional statistical criteria used in RCTs 
provide evidence of significant change.  However, the large sample size ensures observed 
changes are highly significant and interpretation on the basis of P values alone is 
spurious.  Similarly, the observed effect sizes would generally be regarded as ranging 
from the upper end of small (.3 to .49) to medium (.5 to .8) magnitude [10].  While these 
observations support the interpretation that change occurred in this clinical sample, 
neither statistic can be used to support claims that any change was above and beyond that 
produced by the measurement error inherent in the scales, or that the changes were 
clinically important.   
RCI/CSC methodology has a number of advantages: the RCI sets criteria for 
determining whether the magnitude of observed change is spurious (attributable to 
measurement error) and the CSC sets criteria for determining the clinical meaning of the 
observed change.  Using RCI/CSC evidence emerged that for measures of pain, 
emotional distress and self efficacy between one third and one fifth of patients achieved 
clinically significant outcome.  A considerably smaller number (6%, or 1 in 17) achieved 
a clinically significant change on a measure of behavioural activity, the 5 minute walk 
test.  A caveat in interpreting these outcome figures is that the data analysis was 
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performed per protocol rather than as intention-to-treat.  This may therefore over-estimate 
the degree of change in the sample; although our missing data analyses gave no reason to 
suspect that participants with incomplete data sets were substantially different. 
Where data are dichotomised e.g. improved/unimproved it is possible to estimate 
how many patients must be treated in order for one to benefit (Number Needed to Treat – 
NNT).  NNT computations require data from treated and control arms of an RCT [42].  
The NNT statistic is generally not used to express outcomes for psychological treatments 
as most trials employ continuous outcome measures that are expressed as effect sizes in 
meta-analyses [44; 13; 27].  In two exceptions, for pain and gastrointestinal symptoms 
[36] and children with headache [16], NNT values between 2 and 3 have been reported.  
In the current study the values corresponding to the number achieving a clinically 
significant change might be regarded as pseudo-NNT (given the absence of a control 
group).  Thus if 25% achieved a CSC i.e. 1 in 4 responded, gives the crude NNT estimate 
of 4.   
A limitation of the current study concerns the range of measures used in this 
setting.  We examined nine outcomes they were not spread equally across possible 
domains of measurement [44; 45; 51].  Two measures captured pain experience and three 
sampled emotional distress.  The measure of interference with daily activity was limited 
to single numerical rating scale.  The programme did, at various times, use the Sickness 
Impact Profile and the Medical Outcomes Study (SF-36), but neither of these measures 
was used extensively enough to generate a significant sample size.  Only one measure of 
physical capacity was analysed (5 minute walk test) and the degree to which this measure 
can be generalised to other behavioural activities is debatable.  The remaining two 
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measures, the CSQ and PSEQ, might arguably be regarded as process rather than 
outcome measures in that they capture cognitive variables generally deemed to be 
relevant in the successful implementation of CBT.  The evidence that a significant 
proportion of the patients experienced a reliable change in these measures is in accord 
with the intended impact of the treatment but this cannot be taken as prima facie evidence 
that cognitive change was the essential causal process in the treatment programme [6; 
54].  Medication and health care data was collected but the format of the data was not 
reducible to scaled measures.  The present data underscore the requirement to establish 
robust measures for routine clinical use to achieve a data set that captures the critical 
domains [51; 15]. 
RCI/CSC methodology offers advantages over conventional inferential statistics 
in evaluating  programmes but there are several problems associated with the method as 
illustrated within this study.   First the results obtained by this method are a function of 
the estimates of reliability and sample variance.  For example, the impact of the reliability 
on the proportion of individuals achieving a reliable change is evidenced in the contrast 
between the pain measures (r = 0.69) and the 5 minute walk (r = .94) – see Table 3.  The 
lower (test-retest) reliability for the pain measures reflects the fact that pain is not stable 
over time [31].  As a consequence few participants achieved a reliable change for the pain 
measures but it also reflects the fact that a larger shift in the mean level of pain is 
required in order to be able to detect that a reliable change has occurred.  Second, the 
availability and choice of normative data and reference samples influences the 
proportions achieving a clinically significant change.  We approached this problem in a 
pragmatic manner in selecting norms from various sources but the availability of large 
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normative data sets for chronic pain patients over a range of measures would be a 
considerable asset  [46]. This approach led to variation in the criteria used to assess 
clinically significant change and circumvented detailed consideration of the definition of 
clinically significant change in a chronic population.  RCI/CSC methodology uses the 
normative statistical properties of the scales to determine the cut points [34].  Exceptions 
to this were the choice of external norms for the HADS and pain measures, but there is a 
difference between these measures in the way the criteria have been established.  The 
HADS cut score represents the best point for discriminating between depression/non-
depression when an externally defined diagnostic ‘gold standard’ is used [37].  In 
contrast, the criterion for the pain was derived from patients’ global impression of change 
as much improved or better at the end of pharmacological trials [19].  These criteria are 
arguably not fully appropriate for assessing the outcomes in the current setting.  One 
approach that appears promising is to construct criteria on the basis of patient defined 
outcomes [52; 48].  Robinson et al. [48] and Thorne and Morley (in preparation) both 
reported that chronic pain patients estimated that they would regard a change of greater 
than 50% as a successful or acceptable outcome for a range of outcome measures. 
The RCI/CSC methodology explicitly separated patients above and below CSC 
cut points pre-treatment, a feature which has not generally been reported in RCTs of 
psychological treatments for chronic pain.  The separation of the sample pre-treatment 
was particularly noticeable for the measures of emotional adjustment (BDI, HADS).  This 
feature both indicates the heterogeneity within the chronic pain population and suggests 
that unless poor emotional adjustment is included in the selection criterion, a significant 
proportion of patients will show little change on these measures because they are already 
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‘below threshold’.  At the other end of the spectrum, RCI/CSC methodology also 
provides a method for identifying a small proportion of patients who deteriorate during 
the course of treatment.  This phenomenon is recognised within the general 
psychotherapy literature [40] but has barely been investigated in pain management.  
Conventional inferential statistical analyses do not consider either the threshold or the 
deterioration aspects of the current data. 
RCI/CSC methodology is able to rule out measurement error as a plausible 
explanation for change and to determine whether individuals may be regarded as 
clinically improved, but this method cannot answer questions relating to the cause of 
change.  It remains unclear whether observed changes were the result of specific 
treatment effects, non-specific treatment effects, or the mere passage of time. However, 
for the current sample one might infer that the change was not entirely attributable to 
time.  An RCT [56] conducted within this setting using the same treatment protocol 
indicated the superiority of treatment against a 12 week wait list control and a 
generalisation study  [57] showed relatively small advantages to randomised over 
nonrandomised patients treated at INPUT.  It is possible to develop benchmarks of 
treatment outcome for application to routine clinical programmes.  Benchmarks may be 
used to determine whether the magnitude of the average change in the clinic corresponds 
to the average change in RCTs.  Minami et al. [38; 39] have described a strategy and 
developed criteria for psychotherapy efficacy in depression.  Data from RCTs were used 
to generate benchmark effect sizes for pre-treatment – post-treatment comparisons from 
the treatment and control arms of the trials.  These benchmarks controls for the passage 
of time, non-specific and specific treatment effects.  The effect size estimates generated 
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in the current study need to be compared against the corresponding benchmarks 
developed from CBT trials in chronic pain.  Such comparison would facilitate the 
evaluation of the programme effectiveness overall but the effect size statistic does not 
directly relate to clinical effectiveness, for which benchmarks based on categorical 
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